Skip to main content
Celyad reports on data from early-stage study for CAR T-cell candidate

Celyad shared encouraging data from its early-stage dose-escalation study assessing its chimeric antigen receptor T-cell therapy candidate CYAD-01 in patients with blood cancers and solid tumors who have not undergone preconditioning chemotherapy. The results were presented at the annual meeting of the American Society of Hematology.

Full Story: